| 托珠单抗在新型冠状病毒肺炎的应用研究探讨 |
| |
| 引用本文： | 陈碧珊,陈吉生.托珠单抗在新型冠状病毒肺炎的应用研究探讨[J].今日药学,2020(4):225-228. |
| |
| 作者姓名： | 陈碧珊 陈吉生 |
| |
| 作者单位： | 广东药科大学附属第一医院药学部 |
| |
| 摘 要： | 2019年12月以来,新型冠状病毒肺炎(Coronavirus Disease 2019,COVID-19)在武汉暴发并蔓延至全国,给整个社会带来巨大的挑战。部分COVID-19感染者早期发病并不十分凶险,但后期会突然加速进展,病人很快进入多脏器功能衰竭的状态,李兰娟院士等提出了"细胞因子风暴"概念。但目前并没有特效药物,认为IL-6是诱发细胞因子风暴的重要通路,本文结合相关文献的复习和分析,旨在综述IL-6受体阻断剂托珠单抗在新型冠状病毒肺炎危重患者使用的可行性。
|
| 关 键 词： | 新型冠状病毒肺炎 细胞因子风暴 白介素-6 托珠单抗 |
The Clinical Application of Tocilizumab for the Treatment of COVID-19 |
| |
| CHEN Bishan,CHEN Jisheng.The Clinical Application of Tocilizumab for the Treatment of COVID-19[J].Pharmacy Today,2020(4):225-228. |
| |
| Authors: | CHEN Bishan CHEN Jisheng |
| |
| Institution: | (Department of Pharmacy,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou,Guangdong,510080,China) |
| |
| Abstract: | The Coronavirus Disease 2019 (COVID-19) first detected in Wuhan,China,has spread rapidly since December 2019.The early onset of infected patients is not very dangerous,but maybe suffer a sudden acceleration to the state of multiple organ failure.Academician Li and other experts proposed the concept of "cytokine storm",and suggested that IL-6 maybe an important pathway to induce cytokine storm. This paper,combined with the review and analysis of relevant literature,aims to review the feasibility of the il-6 receptor blockers,tocilizumab,in the treatment of severe patients with novel coronavirus pneumonia. |
| |
| Keywords: | COVID-19 cytokine storm interleukin-6 tocilizumab |
| 本文献已被 维普 等数据库收录！ |
|
